Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.

Kjeldsen JW, Iversen TZ, Engell-Noerregaard L, Mellemgaard A, Andersen MH, Svane IM.

Front Immunol. 2018 Sep 19;9:2145. doi: 10.3389/fimmu.2018.02145. eCollection 2018.


[Multicentric reticulohistiocytosis is a rare form of paraneoplasia].

Anderson AM, Todberg T, Kofoed K, Iversen TZ, Andersen M, Hjorth SV, Fassi DE.

Ugeskr Laeger. 2018 Jan 1;180(1). pii: V08170611. Danish.


Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma.

Nitschke NJ, Bjoern J, Iversen TZ, Andersen MH, Svane IM.

Stem Cell Investig. 2017 Sep 21;4:77. doi: 10.21037/sci.2017.08.06. eCollection 2017.


Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.

Kongsted P, Borch TH, Ellebaek E, Iversen TZ, Andersen R, Met Ö, Hansen M, Lindberg H, Sengeløv L, Svane IM.

Cytotherapy. 2017 Apr;19(4):500-513. doi: 10.1016/j.jcyt.2017.01.007. Epub 2017 Feb 15.


Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.

Bjoern J, Iversen TZ, Nitschke NJ, Andersen MH, Svane IM.

Cytotherapy. 2016 Aug;18(8):1043-1055. doi: 10.1016/j.jcyt.2016.05.010.


Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, Hölmich LR, Hendel HW, Met Ö, Andersen MH, Thor Straten P, Svane IM.

Clin Cancer Res. 2016 Aug 1;22(15):3734-45. doi: 10.1158/1078-0432.CCR-15-1879. Epub 2016 Mar 22.


Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy.

Ruhlmann CH, Iversen TZ, Okera M, Muhic A, Kristensen G, Feyer P, Hansen O, Herrstedt J.

Radiother Oncol. 2015 Nov;117(2):333-7. doi: 10.1016/j.radonc.2015.09.014. Epub 2015 Sep 11.


The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.

Iversen TZ, Andersen MH, Svane IM.

Basic Clin Pharmacol Toxicol. 2015 Jan;116(1):19-24. doi: 10.1111/bcpt.12320. Epub 2014 Oct 13. Review.


Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.

Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, Zeyher C, Gouttefangeas C, Thomsen BM, Holm B, Thor Straten P, Mellemgaard A, Andersen MH, Svane IM.

Clin Cancer Res. 2014 Jan 1;20(1):221-32. doi: 10.1158/1078-0432.CCR-13-1560. Epub 2013 Nov 11.


Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients.

Iversen TZ, Brimnes MK, Nikolajsen K, Andersen RS, Hadrup SR, Andersen MH, Bastholt L, Svane IM.

Oncoimmunology. 2013 Feb 1;2(2):e23288.


Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion.

Donia M, Hansen M, Sendrup SL, Iversen TZ, Ellebæk E, Andersen MH, Straten Pt, Svane IM.

J Invest Dermatol. 2013 Feb;133(2):545-52. doi: 10.1038/jid.2012.336. Epub 2012 Sep 27.


Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.

Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met Ö, Hölmich LR, Andersen RS, Hadrup SR, Andersen MH, thor Straten P, Svane IM.

J Transl Med. 2012 Aug 21;10:169. doi: 10.1186/1479-5876-10-169.


Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase.

Munir S, Larsen SK, Iversen TZ, Donia M, Klausen TW, Svane IM, Straten PT, Andersen MH.

PLoS One. 2012;7(4):e34568. doi: 10.1371/journal.pone.0034568. Epub 2012 Apr 23.


Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.

Ellebaek E, Engell-Noerregaard L, Iversen TZ, Froesig TM, Munir S, Hadrup SR, Andersen MH, Svane IM.

Cancer Immunol Immunother. 2012 Oct;61(10):1791-804. Epub 2012 Mar 20.


Supplemental Content

Loading ...
Support Center